抑制剂-话题@MedSci

#抑制剂#

1990篇内容 | 2299人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1852812, encodeId=6bfa185281233, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=2021年11月19日简报：国内31省市累计接种新冠疫苗超24.02亿剂次；国内小分子3CL蛋白酶抑制剂SIM0417也将进入临床试验阶段, objectType=article, longId=220611, objectId=faab2206117b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=faab2206117b, replyNumber=0, likeNumber=63, createdTime=2022-08-10, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=faab2206117b, moduleTitle=2021年11月19日简报：国内31省市累计接种新冠疫苗超24.02亿剂次；国内小分子3CL蛋白酶抑制剂SIM0417也将进入临床试验阶段, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=faab2206117b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852630, encodeId=738f185263076, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=CD38抑制剂Sarclisa/卡非佐米/地塞米松（Kd）治疗晚期多发性骨髓瘤，已获FDA批准, objectType=article, longId=209632, objectId=570b20963284, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=570b20963284, replyNumber=0, likeNumber=72, createdTime=2021-11-09, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=570b20963284, moduleTitle=CD38抑制剂Sarclisa/卡非佐米/地塞米松（Kd）治疗晚期多发性骨髓瘤，已获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=570b20963284)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852820, encodeId=3e5c18528204f, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Front Oncol：PD-1抑制剂camrelizumab（卡瑞利珠单抗）+XELOX化疗联合贝伐珠单抗或regorafenib（瑞戈非尼）作为一线治疗mCRC的有效性和安全性, objectType=article, longId=221101, objectId=e69e221101af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e69e221101af, replyNumber=0, likeNumber=68, createdTime=2022-02-04, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e69e221101af, moduleTitle=Front Oncol：PD-1抑制剂camrelizumab（卡瑞利珠单抗）+XELOX化疗联合贝伐珠单抗或regorafenib（瑞戈非尼）作为一线治疗mCRC的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e69e221101af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852675, encodeId=25d718526e545, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Am J Gastr: 质子泵抑制剂与组胺 2 受体拮抗剂对胃癌的发生风险均没有特殊影响, objectType=article, longId=212334, objectId=8d072123346c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d072123346c, replyNumber=0, likeNumber=75, createdTime=2021-12-18, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d072123346c, moduleTitle=Am J Gastr: 质子泵抑制剂与组胺 2 受体拮抗剂对胃癌的发生风险均没有特殊影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d072123346c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852676, encodeId=36c018526e673, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Brain：DPP4抑制剂使糖尿病帕金森病患者长期获益, objectType=article, longId=212419, objectId=edea2124196c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edea2124196c, replyNumber=0, likeNumber=85, createdTime=2022-05-19, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edea2124196c, moduleTitle=Brain：DPP4抑制剂使糖尿病帕金森病患者长期获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edea2124196c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852730, encodeId=84bb1852e3036, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Neurology：二肽基肽酶-4抑制剂，或可改善患糖尿病痴呆患者认知减退, objectType=article, longId=215758, objectId=c553215e580b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c553215e580b, replyNumber=0, likeNumber=75, createdTime=2022-03-27, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c553215e580b, moduleTitle=Neurology：二肽基肽酶-4抑制剂，或可改善患糖尿病痴呆患者认知减退, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c553215e580b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852683, encodeId=1a371852683e7, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=J Clin Oncol：端粒酶抑制剂Imetelstat可有效治疗骨髓纤维化！, objectType=article, longId=212908, objectId=0f3421290809, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f3421290809, replyNumber=0, likeNumber=82, createdTime=2022-01-06, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f3421290809, moduleTitle=J Clin Oncol：端粒酶抑制剂Imetelstat可有效治疗骨髓纤维化！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f3421290809)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852701, encodeId=9ee11852e01ee, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=J Clin Med：一项初步研究：PCSK9抑制剂依洛尤单抗对心血管疾病高危患者醛固酮分泌的影响, objectType=article, longId=213902, objectId=47232139022c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47232139022c, replyNumber=0, likeNumber=62, createdTime=2021-09-11, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47232139022c, moduleTitle=J Clin Med：一项初步研究：PCSK9抑制剂依洛尤单抗对心血管疾病高危患者醛固酮分泌的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47232139022c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852871, encodeId=b86918528e1b0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JAHA：“PDE5抑制剂”也有短板！会加速腹主动脉瘤恶化, objectType=article, longId=294143, objectId=1ae029414385, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ae029414385, replyNumber=0, likeNumber=64, createdTime=2023-01-03, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ae029414385, moduleTitle=JAHA：“PDE5抑制剂”也有短板！会加速腹主动脉瘤恶化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ae029414385)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852615, encodeId=db29185261516, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=SMO抑制剂上市申请获CDE优先审评，治疗基底细胞癌, objectType=article, longId=208132, objectId=72842081322b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72842081322b, replyNumber=0, likeNumber=105, createdTime=2021-08-16, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72842081322b, moduleTitle=SMO抑制剂上市申请获CDE优先审评，治疗基底细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=72842081322b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852649, encodeId=96201852649d8, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Gut | 警惕！长期使用质子泵抑制剂竟然会增加2型糖尿病的风险，而且时间越久风险越大！, objectType=article, longId=211002, objectId=b9a1211002c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9a1211002c6, replyNumber=0, likeNumber=91, createdTime=2022-04-04, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9a1211002c6, moduleTitle=Gut | 警惕！长期使用质子泵抑制剂竟然会增加2型糖尿病的风险，而且时间越久风险越大！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9a1211002c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852760, encodeId=2e7d1852e604c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Eur J Cancer：免疫检查点抑制剂在老年头颈部鳞癌患者中的有效性和安全性, objectType=article, longId=217545, objectId=e09321e54552, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e09321e54552, replyNumber=0, likeNumber=92, createdTime=2022-02-22, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e09321e54552, moduleTitle=Eur J Cancer：免疫检查点抑制剂在老年头颈部鳞癌患者中的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e09321e54552)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852800, encodeId=1be31852800a7, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Alz Res Therapy：胆碱酯酶抑制剂使用，或和认知功能变化无关, objectType=article, longId=219920, objectId=b0cf219920d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0cf219920d6, replyNumber=0, likeNumber=95, createdTime=2022-03-09, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0cf219920d6, moduleTitle=Alz Res Therapy：胆碱酯酶抑制剂使用，或和认知功能变化无关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0cf219920d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852608, encodeId=82301852608bc, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=SCIENCE：杨胜勇/雷剑及/郑永勇等合作发现具有抗病毒活性的SARS-CoV-2 Mpro抑制剂, objectType=article, longId=207328, objectId=9d7320e3285c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d7320e3285c, replyNumber=0, likeNumber=75, createdTime=2021-07-07, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d7320e3285c, moduleTitle=SCIENCE：杨胜勇/雷剑及/郑永勇等合作发现具有抗病毒活性的SARS-CoV-2 Mpro抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d7320e3285c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852803, encodeId=dcae1852803ca, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Clin Cancer Res：碱基切除修复抑制剂TRC102联合培美曲塞-顺铂-放疗标准方案治疗晚期非鳞状非小细胞肺癌, objectType=article, longId=220113, objectId=b4a822011305, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4a822011305, replyNumber=0, likeNumber=106, createdTime=2022-04-22, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4a822011305, moduleTitle=Clin Cancer Res：碱基切除修复抑制剂TRC102联合培美曲塞-顺铂-放疗标准方案治疗晚期非鳞状非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4a822011305)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852607, encodeId=8e5d185260e07, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Clin Cancer Res：DNA甲基转移酶抑制剂Guadecitabine联合顺铂和吉西他滨治疗实体恶性肿瘤, objectType=article, longId=207297, objectId=95e820e29758, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=95e820e29758, replyNumber=0, likeNumber=103, createdTime=2021-04-25, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=95e820e29758, moduleTitle=Clin Cancer Res：DNA甲基转移酶抑制剂Guadecitabine联合顺铂和吉西他滨治疗实体恶性肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=95e820e29758)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852674, encodeId=b11a18526e41a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Gut：颠覆！质子泵抑制剂长期使用居然会增加胃癌风险！, objectType=article, longId=212310, objectId=580621231050, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=580621231050, replyNumber=0, likeNumber=73, createdTime=2022-05-07, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=580621231050, moduleTitle=Gut：颠覆！质子泵抑制剂长期使用居然会增加胃癌风险！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=580621231050)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852671, encodeId=210318526e1c2, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=KRAS抑制剂获美国FDA加速批准，治疗非小细胞肺癌, objectType=article, longId=212097, objectId=f6de21209e2c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6de21209e2c, replyNumber=0, likeNumber=76, createdTime=2022-03-18, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6de21209e2c, moduleTitle=KRAS抑制剂获美国FDA加速批准，治疗非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6de21209e2c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852713, encodeId=e5761852e133b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=降糖药SGLT-2抑制剂也能治心衰？看完本文马上掌握！, objectType=article, longId=214626, objectId=4e1d214626dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e1d214626dd, replyNumber=0, likeNumber=70, createdTime=2022-03-03, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e1d214626dd, moduleTitle=降糖药SGLT-2抑制剂也能治心衰？看完本文马上掌握！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e1d214626dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852681, encodeId=25ed1852681c6, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=J Immunother Cancer: IDO抑制剂indoximod联合PD1抑制剂帕博利珠单抗（pembrolizumab）治疗晚期黑色素瘤的疗效和安全性, objectType=article, longId=212747, objectId=5467212e47b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5467212e47b0, replyNumber=0, likeNumber=71, createdTime=2021-09-15, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5467212e47b0, moduleTitle=J Immunother Cancer: IDO抑制剂indoximod联合PD1抑制剂帕博利珠单抗（pembrolizumab）治疗晚期黑色素瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5467212e47b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

抑制剂

2020-05-29

仁心济世 (审核中...)

前往app查看评论内容

#抑制剂#

2021年11月19日简报：国内31省市累计接种新冠疫苗超24.02亿剂次；国内小分子3CL蛋白酶抑制剂SIM0417也将进入临床试验阶段

2022-08-10

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

CD38抑制剂Sarclisa/卡非佐米/地塞米松（Kd）治疗晚期多发性骨髓瘤，已获FDA批准

2021-11-09

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Front Oncol：PD-1抑制剂camrelizumab（卡瑞利珠单抗）+XELOX化疗联合贝伐珠单抗或regorafenib（瑞戈非尼）作为一线治疗mCRC的有效性和安全性

2022-02-04

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Am J Gastr: 质子泵抑制剂与组胺 2 受体拮抗剂对胃癌的发生风险均没有特殊影响

2021-12-18

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Brain：DPP4抑制剂使糖尿病帕金森病患者长期获益

2022-05-19

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Neurology：二肽基肽酶-4抑制剂，或可改善患糖尿病痴呆患者认知减退

2022-03-27

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

J Clin Oncol：端粒酶抑制剂Imetelstat可有效治疗骨髓纤维化！

2022-01-06

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

J Clin Med：一项初步研究：PCSK9抑制剂依洛尤单抗对心血管疾病高危患者醛固酮分泌的影响

2021-09-11

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JAHA：“PDE5抑制剂”也有短板！会加速腹主动脉瘤恶化

2023-01-03

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

SMO抑制剂上市申请获CDE优先审评，治疗基底细胞癌

2021-08-16

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Gut | 警惕！长期使用质子泵抑制剂竟然会增加2型糖尿病的风险，而且时间越久风险越大！

2022-04-04

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Eur J Cancer：免疫检查点抑制剂在老年头颈部鳞癌患者中的有效性和安全性

2022-02-22

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Alz Res Therapy：胆碱酯酶抑制剂使用，或和认知功能变化无关

2022-03-09

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

SCIENCE：杨胜勇/雷剑及/郑永勇等合作发现具有抗病毒活性的SARS-CoV-2 Mpro抑制剂

2021-07-07

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Clin Cancer Res：碱基切除修复抑制剂TRC102联合培美曲塞-顺铂-放疗标准方案治疗晚期非鳞状非小细胞肺癌

2022-04-22

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Clin Cancer Res：DNA甲基转移酶抑制剂Guadecitabine联合顺铂和吉西他滨治疗实体恶性肿瘤

2021-04-25

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Gut：颠覆！质子泵抑制剂长期使用居然会增加胃癌风险！

2022-05-07

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

KRAS抑制剂获美国FDA加速批准，治疗非小细胞肺癌

2022-03-18

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

降糖药SGLT-2抑制剂也能治心衰？看完本文马上掌握！

2022-03-03

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

J Immunother Cancer: IDO抑制剂indoximod联合PD1抑制剂帕博利珠单抗（pembrolizumab）治疗晚期黑色素瘤的疗效和安全性

2021-09-15

科室
- - 订阅+
  - 更多科室
工具
服务